Double-blind investigational anti-arrhythmic
3163K1-200
Phase 2 small_molecule terminated
Quick answer
Double-blind investigational anti-arrhythmic for Arrhythmias is a Phase 2 program (small_molecule) at Wyeth is now a wholly owned subsidiary of Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Wyeth is now a wholly owned subsidiary of Pfizer
- Indication
- Arrhythmias
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated